February 7, 2014
The Second Wave Arrives
Two more HCV drugs were newly approved in late 2013: the protease inhibitor simeprevir (Olysio) and the nucleotide polymerase inhibitor sofosbuvir (Sovaldi).
By comparison to the two previously approved HCV protease inhibitors, simeprevir appears to be significantly more friendly toward coadministration with HIV medications (particularly HIV protease inhibitors) and has a high efficacy rate in HCV treatment-naive coinfected patients, even allowing many to dramatically shorten the typical course of HCV therapy. However, the drug must still be coadministered with peginterferon, leaving toxicity as a major issue.
Peginterferon is also part of a sofosbuvir-containing regimen at the moment, but only for genotype 1 patients. For patients with genotype 2 or 3, the drug is dosed alongside only ribavirin, and dramatically lower adverse event rates accompany that indication. Sofosbuvir also appears to have virtually no interactions with HIV antiretrovirals.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|Which Hepatitis C Treatment to Start in 2016|
|This Week in HIV Research: Antibody Suppresses HIV; Investigational Drug BMS-986001; and Quality of Care on Mortality|
|This Week in HIV Research: Tenofovir Resistance Alarmingly Common; Ongoing HIV Replication Replenishes Reservoirs; and More|
|High Liver Enzymes Signal Serious Disease in HIV-Positive Individuals Without Hepatitis|
|This Week in HIV Research: Smoking Associated With Poor HIV Outcomes; How Gay Men Decide on Condomless Sex; and More|
|This Week in HIV Research: Reasons for Skipping Meds; Tenofovir Monotherapy PrEP Failures; and Increasing HIV Test Acceptance|